glp 1 receptor antagonists GLP-1 agonists show promise in treating substance use disorders Glucagon-like peptide-1 receptor: mechanisms and

Register today:

Keywords: GLP-1, inflammation, inflammatory bowel disease, smooth muscle Corrigendum for this paper has been published Introduction Inflammatory conditions of the gastrointestinal tract (GIT) are a growing problem in the industrialized nations, affecting the quality of the patients life and having significant financial burden

The evolving public perception of obesity stigma reflects a gradual shift toward recognizing obesity as a complex medical condition influenced by biological and environmental factors, rather than a simple matter of personal responsibility

This is the first generic glucagon-like peptide-1 (GLP-1) agonist approved for use as an adjunct to diet and exercise for chronic weight management

MHT received funding from the European Research Council ERC AdG HypoFlam no

Drug Metab Dispos